New York – A study, published in the journal Science Advances, showed an experimental single-dose, intranasal Covid-19 vaccine, that uses harmless parainfluenza virus 5 (PIV5) – has shown potential for full protection in mice against infectious disease. It is done to deliver the SARS-CoV-2 spike protein into cells where it prompts an immune response that protects against Covid-19 infection. Paul McCray, Professor of Paediatrics-Pulmonary Medicine, and Microbiology and Immunology at the University of Iowa’s Carver College of Medicine., said: “The currently available vaccines against Covid-19 are very successful, but the majority of the world’s population is still unvaccinated and there is a critical need for more vaccines that are easy to use and effective at stopping disease and transmission. If this new Covid-19 vaccine proves effective in people, it may help block SARS-CoV-2 transmission and help control the Covid-19 pandemic.” The inhaled PIV5 vaccine developed by the team targets mucosal cells that line the nasal passages and airways. These cells are the main entry point for most SARS-CoV-2 infections and the site of early virus replication. Due it is given intranasally, the vaccine may also be easier to administer, especially for those who have a fear of needles, the team said.